Axatilimab with Corticosteroids for Chronic Graft-Versus-Host Disease

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Recruiting Phase 3 Interventional Study
Chronic Graft-versus-host-disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
240 (estimated)
Sponsor
Incyte Corporation · Industry
Who this trial is looking for

This trial is looking for people aged 12 and older who have just been diagnosed with moderate or severe chronic graft-versus-host disease. Participants will receive a treatment called axatilimab along with corticosteroids to see how effective it is compared to a placebo.

Are You a Good Fit for This Trial?
Rules you out Acute graft-versus-host diseaseInfectionHeart diseaseKidney disease

You may be able to join if

  • I am 12 years old or older.
  • I have been diagnosed with moderate or severe chronic graft-versus-host disease.
  • I have undergone an allogeneic hematopoietic cell transplant.
  • My blood cell counts are stable.
  • I agree to avoid pregnancy or fathering children.

You may not be able to join if

  • I have had more than one previous allogeneic transplant.
  • I have symptoms of acute graft-versus-host disease.
  • I have received more than 7 days of corticosteroid treatment for this condition.
  • I have received other treatments for chronic graft-versus-host disease.
  • I have an uncontrolled infection.
  • I have a significant heart condition.
  • I have severe kidney problems.
  • I am pregnant or breastfeeding.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * ≥ 12 years of age at the time of informed consent. * New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy. * History of allo-HCT from any donor HLA type (related or unrela…
Contacts

Incyte Corporation Call Center (US)

1.855.463.3463

medinfo@incyte.com

CONTACT

Incyte Corporation Call Center (ex-US)

+800 00027423

eumedinfo@incyte.com

CONTACT